-+ 0.00%
-+ 0.00%
-+ 0.00%

ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients

Benzinga·10/25/2026 17:59:32
語音播報

ARR-217 was generally well-tolerated. ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program